The cell-binding carboxyterminal undecapeptide of SV40 tumour antigen provides protective cell-dependent immunity.
This paper describes the use of the synthetic carboxyterminal undecapeptide of large SV40 tumour antigen, lys698-thr708 (KT) to protect Balb/c mice against growth of subcutaneously transplanted tumorigenic SV40-transformed cells (VLM). The vaccine was prepared by conjugation of KT with 3-(2-pyridyldithio)propionic acid N-hydroxysuccinimide (SPDP). Addition of the SPDP-derivative of KT to syngeneic spleen cells rendered KT covalently linked to free thiol-groups of the cell membranes by the formation of -S-S-CH2-CH2-CO-epsilon-NH-lys698 bonds. Vaccination with KT-conjugated cells was intraperitoneal. Alternatively, KT-conjugated cells were generated in the peritoneum by injection of PDP-KT ((2-pyridyldithio)propionic acid-KT). As a control 60Co-irradiated VLM cells were used. In five experiments all VLM-vaccinated and the majority of the PDP-KT-(or KT-spleen cell)-vaccinated mice were protected against tumour growth. However, mice pretreated with saline, unconjugated spleen cells, free KT, KT conjugated to bovine serum albumin, or KT with incomplete Freund's adjuvant developed tumours. Treatment of PDP-KT-vaccinated mice with anti-CD4 or anti-CD8 immunoglobulin abolished tumour immunity completely. Thus, covalent binding of the carboxyterminal undecapeptide of SV40 tumour antigen to viable, untransformed cells yielded a vaccine which protects Balb/c mice against SV40 tumours.
Hanagarth
H G
HG
Abteilung Virologie, Universität Freiburg, Germany.
Obert
M
M
Hess
R
R
Haessler
C
C
Braun
D G
DG
Brandner
G
G
D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000818:Animals; D000957:Antigens, Viral, Tumor / Q000008:administration & dosage / Q000378:metabolism; D015704:CD4 Antigens; D016827:CD8 Antigens; D002462:Cell Membrane / Q000378:metabolism; D005260:Female; D007111:Immunity, Cellular; D007136:Immunoglobulins / Q000008:administration & dosage; D051379:Mice; D008807:Mice, Inbred BALB C; D009842:Oligopeptides / Q000008:administration & dosage / Q000276:immunology* / Q000378:metabolism; D030361:Papillomavirus Infections / Q000517:prevention & control; D011485:Protein Binding; D013539:Simian virus 40 / Q000235:genetics / Q000276:immunology*; D014412:Tumor Virus Infections / Q000517:prevention & control; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000494:pharmacology; D014765:Viral Vaccines / Q000008:administration & dosage / Q000494:pharmacology
D000276:Adjuvants, Immunologic; D000957:Antigens, Viral, Tumor; D015704:CD4 Antigens; D016827:CD8 Antigens; D007136:Immunoglobulins; C089279:K698-T708 undecapeptide; D009842:Oligopeptides; D014614:Vaccines, Synthetic; D014765:Viral Vaccines